Lipoprotein(a) in patients with coronary atherosclerosis.

Elsherif, Yasmen Mohamed; Abdelnaem, Emad Allam; Makram, Naglaa; Kamel, Asmaa Khalaf Allah

doi:10.21608/mjmr.2023.209305.1392

Lipoprotein(a) in patients with coronary atherosclerosis.

Articles in Press

Document Type : Original Article

Authors

¹ faculty of medicine minia universty

² Clinical pathology department, Faculty of medicine, Minia university

³ Clinical Pathology, Faculty of Medicine, Minia University, Egypt

⁴ Department of Pediatrics, Faculty of Medicine, Minia University, El-Minia, Egypt.

10.21608/mjmr.2023.209305.1392

Abstract

Purpose of study: Cardiovascular diseases (CVDs) are the main cause of death all over the world. Atherosclerotic coronary heart disease is the major cause of mortality associated CVD and represents about 45% of all cases. Despite the therapeutic improvement in treatment of CVD, it stills the main cause of mortality worldwide, representing a higher portion of health cost than any other disease. Lipoprotein (a) (Lp[a]) concentration is considered to be causal in the progression of atherosclerotic cardiovascular disease (ASCVD). The aim of this study is to assess the impact of high lipoprotein (a) on severity of coronary atherosclerosis.

Basic procedures: The study was conducted on one hundred subjects including 35 apparently healthy individuals (group II) with matched age and sex as a control group and 65 patients diagnosed having coronary artery atherosclerosis by angiographic imaging. They were selected from the Cardiology Clinic, Faculty of Medicine, Minia University Hospital during the period from November 2021 to June 2022 (group I). The diseased subjects included patients diagnosed as coronary atherosclerosis by angiography and on treatment.

Main findings: results of this study revealed that there was no statistically significant difference regarding gender and age distributions between the atherosclerotic subjects and the control groups, however patients with atherosclerosis showed statistically significant higher Lp (a) levels than control group. Principle conclusion: Overall, the findings of this study indicate that lipoprotein (a) elevation was evident in patients with coronary artery atherosclerosis and so it should be targeted in therapy and risk assessment of coronary artery atherosclerosis.

Keywords

Main Subjects